Related references
Note: Only part of the references are listed.Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis
Zuzhen Ou et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2018)
Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials
Patrick Fleming et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo-controlled clinical trials
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Cardiovascular and cerebrovascular events among patients receiving omalizumab: Results from EXCELS, a prospective cohort study in moderate to severe asthma
Carlos Iribarren et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2017)
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
B. Popovic et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma
Diego Bagnasco et al.
INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY (2016)
Tristetraprolin exerts tumor suppressive functions on the tumorigenesis of glioma by targeting IL-13
Bo Zeng et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2016)
Effect of Subcutaneous Dupilumab on Nasal Polyp Burden in Patients With Chronic Sinusitis and Nasal Polyposis A Randomized Clinical Trial
Claus Bachert et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Enhanced protection from fibrosis and inflammation in the combined absence of IL-13 and IFN-γ
Thirumalai R. Ramalingam et al.
JOURNAL OF PATHOLOGY (2016)
Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial
Sally Wenzel et al.
LANCET (2016)
Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial
Diamant Thaci et al.
LANCET (2016)
IL-13 from intraepithelial lymphocytes regulates tissue homeostasis and protects against carcinogenesis in the skin
Tim Dalessandri et al.
NATURE COMMUNICATIONS (2016)
Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials
Nicola A. Hanania et al.
LANCET RESPIRATORY MEDICINE (2016)
Immune Modulation of Cardiac Repair and Regeneration: The Art of Mending Broken Hearts
Ivana Zlatanova et al.
FRONTIERS IN CARDIOVASCULAR MEDICINE (2016)
Th2 cytokines impair innate immune responses to rhinovirus in respiratory epithelial cells
M. Contoli et al.
ALLERGY (2015)
Modulation of pulmonary fibrosis by IL-13Rα2
Robert V. Lumsden et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2015)
The Causal Role of IL-4 and IL-13 in Schistosoma mansoni Pulmonary Hypertension
Rahul Kumar et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2015)
Pharmacokinetics of tralokinumab in adolescents with asthma: implications for future dosing
Paul G. Baverel et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Current novel approaches in systemic therapy of atopic dermatitis: specific inhibition of cutaneous Th2 polarized inflammation and itch
Thomas Werfel et al.
CURRENT OPINION IN ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Targeting of IL-4 and IL-13 receptors for cancer therapy
Akiko Suzuki et al.
CYTOKINE (2015)
Strategies targeting the IL-4/IL-13 axes in disease
Richard D. May et al.
CYTOKINE (2015)
IL-4 and IL-13 signaling in allergic airway disease
Naina Gour et al.
CYTOKINE (2015)
Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study
Walter Reinisch et al.
GUT (2015)
Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies
Nicola A. Hanania et al.
THORAX (2015)
Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal Adenocarcinoma
Sarah Derks et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial
Christopher E. Brightling et al.
LANCET RESPIRATORY MEDICINE (2015)
Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study
Silvio Danese et al.
GUT (2015)
Conditional IL-4/IL-13-deficient mice reveal a critical role of innate immune cells for protective immunity against gastrointestinal helminths
K. Oeser et al.
MUCOSAL IMMUNOLOGY (2015)
IL-13R alpha 2 mediates PNR-induced migration and metastasis in ER alpha-negative breast cancer
Z. Zhao et al.
ONCOGENE (2015)
Targeting IL13Ralpha2 activates STAT6-TP63 pathway to suppress breast cancer lung metastasis
Panagiotis Papageorgis et al.
BREAST CANCER RESEARCH (2015)
IL4 Receptor ILR4α Regulates Metastatic Colonization by Mammary Tumors through Multiple Signaling Pathways
Katherine T. Venmar et al.
CANCER RESEARCH (2014)
Interleukin-13 Deficiency Aggravates Healing and Remodeling in Male Mice After Experimental Myocardial Infarction
Ulrich Hofmann et al.
CIRCULATION-HEART FAILURE (2014)
The effects of lebrikizumab in patients with mild asthma following whole lung allergen challenge
H. Scheerens et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2014)
IL-4 and IL-13 receptors: Roles in immunity and powerful vaccine adjuvants
Charani Ranasinghe et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2014)
Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: A randomized trial
Erika H. De Boever et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Incidence of malignancy in patients with moderate-to-severe asthma treated with or without omalizumab
Aidan Long et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)
Interleukin-13-Mediated Paneth Cell Degranulation and Antimicrobial Peptide Release
Silvia Stockinger et al.
JOURNAL OF INNATE IMMUNITY (2014)
Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis
Lisa A. Beck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Host protective roles of type 2 immunity: Parasite killing and tissue repair, flip sides of the same coin
Judith E. Allen et al.
SEMINARS IN IMMUNOLOGY (2014)
A phase 1, randomized, placebo-controlled, dose-escalation study of an anti-IL-13 monoclonal antibody in healthy subjects and mild asthmatics
Peter Hodsman et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Dynamic Mast Cell-Stromal Cell Interactions Promote Growth of Pancreatic Cancer
Ying Ma et al.
CANCER RESEARCH (2013)
Reduced type II interleukin-4 receptor signalling drives initiation, but not progression, of colorectal carcinogenesis: evidence from transgenic mouse models and human casecontrol epidemiological observations
Nicola Ingram et al.
CARCINOGENESIS (2013)
A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma
Edward Piper et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
Targeting the IL-4/IL-13 signaling pathway sensitizes Hodgkin lymphoma cells to chemotherapeutic drugs
Antonino Natoli et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Dose-ranging study of lebrikizumab in asthmatic patients not receiving inhaled steroids
Michael Noonan et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
IL-13 receptor α2 contributes to development of experimental allergic asthma
Weiguo Chen et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2013)
Dupilumab in Persistent Asthma with Elevated Eosinophil Levels
Sally Wenzel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Reduced Interleukin-4 Receptor α Expression on CD8+ T Cells Correlates with Higher Quality Anti-Viral Immunity
Danushka K. Wijesundara et al.
PLOS ONE (2013)
Preclinical development of CAT-354, an IL-13 neutralizing antibody, for the treatment of severe uncontrolled asthma
R. D. May et al.
BRITISH JOURNAL OF PHARMACOLOGY (2012)
Interleukin-13 protects from atherosclerosis and modulates plaque composition by skewing the macrophage phenotype
Larissa Cardilo-Reis et al.
EMBO MOLECULAR MEDICINE (2012)
IL-13 regulates cancer invasion and metastasis through IL-13Rα2 via ERK/AP-1 pathway in mouse model of human ovarian cancer
Toshio Fujisawa et al.
INTERNATIONAL JOURNAL OF CANCER (2012)
Omalizumab and the risk of malignancy: Results from a pooled analysis
William Busse et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)
New Paradigms in Type 2 Immunity
Bali Pulendran et al.
SCIENCE (2012)
Transcriptional regulation by STAT6
Shreevrat Goenka et al.
IMMUNOLOGIC RESEARCH (2011)
Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous Signaling
Linda C. Hsi et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Lebrikizumab Treatment in Adults with Asthma
Jonathan Corren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Diversity and dialogue in immunity to helminths
Judith E. Allen et al.
NATURE REVIEWS IMMUNOLOGY (2011)
IL-4 and IL-13 exposure during mucociliary differentiation of bronchial epithelial cells increases antimicrobial activity and expression of antimicrobial peptides
Suzanne Zuyderduyn et al.
RESPIRATORY RESEARCH (2011)
A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4Rα Antagonist, in Patients with Asthma
Jonathan Corren et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Alternative activation of macrophages by IL-4 impairs phagocytosis of pathogens but potentiates microbial-induced signalling and cytokine secretion
Audrey Varin et al.
BLOOD (2010)
An open-label, single-dose bioavailability study of the pharmacokinetics of CAT-354 after subcutaneous and intravenous administration in healthy males
Chad K. Oh et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Epithelial interleukin-4 receptor expression promotes colon tumor growth
Felicitas L. Koller et al.
CARCINOGENESIS (2010)
Cytokine interactions that determine the outcome of mycobacterial infection of macrophages
Rajko Reljic et al.
CYTOKINE (2010)
Interleukin-13 stimulation of the mediastinal B-cell lymphoma cell line Karpas-1106P induces a phenotype resembling the Hodgkin lymphoma cell line L1236
Erik Andersson et al.
EXPERIMENTAL HEMATOLOGY (2010)
A phase 1 study evaluating the pharmacokinetics, safety and tolerability of repeat dosing with a human IL-13 antibody (CAT-354) in subjects with asthma
Dave Singh et al.
BMC PULMONARY MEDICINE (2010)
IL-4Rα Responsiveness of Non-CD4 T Cells Contributes to Resistance in Schistosoma mansoni Infection in Pan-T Cell-Specific IL-4Rα-Deficient Mice
Benjamin Dewals et al.
AMERICAN JOURNAL OF PATHOLOGY (2009)
Leishmania major: Interleukin-13 increases the infection-induced hyperalgesia and the levels of interleukin-1β and interleukin-12 in rats
Marc E. Haber et al.
EXPERIMENTAL PARASITOLOGY (2009)
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
David Moher et al.
PLOS MEDICINE (2009)
Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system
Sherry L. LaPorte et al.
CELL (2008)
IL-13 pre-treatment of murine peritoneal macrophages increases their anti-Toxoplasma gondii activity induced by lipopolysaccharides
Helene Authier et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2008)
Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation
Jong Myun Park et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Effect of an interieukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies
Sally Wenzel et al.
LANCET (2007)
IL-13 induces disease-promoting type 2 cytokines, alternatively activated macrophages and allergic inflammation during pulmonary infection of mice with Cryptococcus neoformans
Uwe Mueller et al.
JOURNAL OF IMMUNOLOGY (2007)
Deletion of IL-4Rα on CD4 T cells renders BALB/c mice resistant to Leishmania major infection
Magdalena Radwanska et al.
PLOS PATHOGENS (2007)
Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection
A. A. Cruz et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2007)
Expression of IL-4 receptor on non-bone marrow-derived cells is necessary for the timely elimination of Strongyloides venezuelensis in mice, but not for intestinal IL-4 production
Deborah Negrao-Correa et al.
INTERNATIONAL JOURNAL FOR PARASITOLOGY (2006)
Share Paper
